IBDEI0KH ; ; 04-FEB-2020
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,9036,0)
 ;;=N03.4^^69^617^13
 ;;^UTILITY(U,$J,358.3,9036,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9036,1,3,0)
 ;;=3^Chr nephritic syndrome w/ diffuse endocaplry prolif glomrlneph
 ;;^UTILITY(U,$J,358.3,9036,1,4,0)
 ;;=4^N03.4
 ;;^UTILITY(U,$J,358.3,9036,2)
 ;;=^5015525
 ;;^UTILITY(U,$J,358.3,9037,0)
 ;;=N03.5^^69^617^16
 ;;^UTILITY(U,$J,358.3,9037,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9037,1,3,0)
 ;;=3^Chr nephritic syndrome w/ diffuse mesangiocap glomrlneph
 ;;^UTILITY(U,$J,358.3,9037,1,4,0)
 ;;=4^N03.5
 ;;^UTILITY(U,$J,358.3,9037,2)
 ;;=^5015526
 ;;^UTILITY(U,$J,358.3,9038,0)
 ;;=N03.6^^69^617^11
 ;;^UTILITY(U,$J,358.3,9038,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9038,1,3,0)
 ;;=3^Chr nephritic syndrome w/ dense deposit disease
 ;;^UTILITY(U,$J,358.3,9038,1,4,0)
 ;;=4^N03.6
 ;;^UTILITY(U,$J,358.3,9038,2)
 ;;=^5015527
 ;;^UTILITY(U,$J,358.3,9039,0)
 ;;=N03.7^^69^617^12
 ;;^UTILITY(U,$J,358.3,9039,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9039,1,3,0)
 ;;=3^Chr nephritic syndrome w/ diffuse crescentic glomrlneph
 ;;^UTILITY(U,$J,358.3,9039,1,4,0)
 ;;=4^N03.7
 ;;^UTILITY(U,$J,358.3,9039,2)
 ;;=^5015528
 ;;^UTILITY(U,$J,358.3,9040,0)
 ;;=N03.8^^69^617^19
 ;;^UTILITY(U,$J,358.3,9040,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9040,1,3,0)
 ;;=3^Chr nephritic syndrome w/ other morphologic changes
 ;;^UTILITY(U,$J,358.3,9040,1,4,0)
 ;;=4^N03.8
 ;;^UTILITY(U,$J,358.3,9040,2)
 ;;=^5015529
 ;;^UTILITY(U,$J,358.3,9041,0)
 ;;=N03.9^^69^617^20
 ;;^UTILITY(U,$J,358.3,9041,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9041,1,3,0)
 ;;=3^Chr nephritic syndrome w/ unsp morphologic changes
 ;;^UTILITY(U,$J,358.3,9041,1,4,0)
 ;;=4^N03.9
 ;;^UTILITY(U,$J,358.3,9041,2)
 ;;=^5015530
 ;;^UTILITY(U,$J,358.3,9042,0)
 ;;=N04.0^^69^617^59
 ;;^UTILITY(U,$J,358.3,9042,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9042,1,3,0)
 ;;=3^Nephrotic syndrome w/ minor glomerular abnormality
 ;;^UTILITY(U,$J,358.3,9042,1,4,0)
 ;;=4^N04.0
 ;;^UTILITY(U,$J,358.3,9042,2)
 ;;=^5015531
 ;;^UTILITY(U,$J,358.3,9043,0)
 ;;=N04.1^^69^617^58
 ;;^UTILITY(U,$J,358.3,9043,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9043,1,3,0)
 ;;=3^Nephrotic syndrome w/ focal & segmental glomerular lesions
 ;;^UTILITY(U,$J,358.3,9043,1,4,0)
 ;;=4^N04.1
 ;;^UTILITY(U,$J,358.3,9043,2)
 ;;=^5015532
 ;;^UTILITY(U,$J,358.3,9044,0)
 ;;=N04.2^^69^617^55
 ;;^UTILITY(U,$J,358.3,9044,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9044,1,3,0)
 ;;=3^Nephrotic syndrome w/ diffuse membranous glomerulonephritis
 ;;^UTILITY(U,$J,358.3,9044,1,4,0)
 ;;=4^N04.2
 ;;^UTILITY(U,$J,358.3,9044,2)
 ;;=^5015533
 ;;^UTILITY(U,$J,358.3,9045,0)
 ;;=N04.3^^69^617^56
 ;;^UTILITY(U,$J,358.3,9045,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9045,1,3,0)
 ;;=3^Nephrotic syndrome w/ diffuse mesangial prolif glomrlneph
 ;;^UTILITY(U,$J,358.3,9045,1,4,0)
 ;;=4^N04.3
 ;;^UTILITY(U,$J,358.3,9045,2)
 ;;=^5015534
 ;;^UTILITY(U,$J,358.3,9046,0)
 ;;=N04.4^^69^617^54
 ;;^UTILITY(U,$J,358.3,9046,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9046,1,3,0)
 ;;=3^Nephrotic syndrome w/ diffuse endocaplry prolif glomrlneph
 ;;^UTILITY(U,$J,358.3,9046,1,4,0)
 ;;=4^N04.4
 ;;^UTILITY(U,$J,358.3,9046,2)
 ;;=^5015535
 ;;^UTILITY(U,$J,358.3,9047,0)
 ;;=N04.5^^69^617^57
 ;;^UTILITY(U,$J,358.3,9047,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9047,1,3,0)
 ;;=3^Nephrotic syndrome w/ diffuse mesangiocapillary glomrlneph
